University of Texas Health Science Center at Houston, Houston, TX, United States.
Baylor College of Medicine, Houston, TX, United States.
Diabetes Res Clin Pract. 2019 Mar;149:78-88. doi: 10.1016/j.diabres.2019.01.033. Epub 2019 Feb 5.
Tobacco use disorder (TUD), in particular cigarette smoking, contributes significantly to the macro- and micro-vascular complications of type 2 diabetes mellitus (DM). Persons with DM who regularly use tobacco products are twice as likely to experience mortality and negative health outcomes. Despite these risks, TUD remains prevalent in persons with DM. The objective of this integrative review is to summarize the relationship between TUD and DM based on epidemiological and preclinical biological evidence. We conclude with a review of the literature on the glucagon-like peptide-1 (GLP-1) as a potential treatment target for addressing comorbid TUD in smokers with DM.
烟草使用障碍（TUD），特别是吸烟，会显著导致 2 型糖尿病（DM）的大血管和微血管并发症。经常使用烟草制品的 DM 患者，其死亡率和不良健康结局的风险增加一倍。尽管存在这些风险，但 TUD 在 DM 患者中仍然很普遍。本综合综述的目的是根据流行病学和临床前生物学证据总结 TUD 与 DM 之间的关系。最后，我们回顾了胰高血糖素样肽-1（GLP-1）作为治疗合并 TUD 的 DM 吸烟者的潜在治疗靶点的文献。
